Global Peanut Allergy Treatment Market Size & Trends Report Segmented by Drug Type (Antihistamines, Epinephrine, Immunotherapies), Route of Administration (Oral, Injectable), Age Group (Paediatric, Adult), Distribution Channel (Hospital, Retail Pharmacies), & Regional Forecast to 2031

The peanut allergy treatment market includes treatments which are either used to prevent, reduce, or manage immune reactions triggered by peanut exposure. This encompasses oral immunotherapy products, biologics targeting allergic pathways, epinephrine-based emergency treatments, and emerging approaches. The market also spans supportive diagnostics and patient management protocols that enable controlled desensitization or mitigate the risks of severe allergic responses. These treatments are primarily used in pediatric populations, but clinical trials are now increasingly expanding to adults, acknowledging the fact that peanut allergy often persists throughout life.

Rising prevalence of peanut allergies in pediatric populations

The surge in the number of children with peanut allergies remains a central factor driving the peanut allergy treatment market. Epidemiological studies indicate a steady rise in food allergies over the past two decades, with peanut allergy representing one of the most persistent and severe forms, frequently affecting children under 18. Moreover, an article published by NIH also states that peanut allergy is more common in Western Nations, likely due to a combination of genetic factors, environmental factors, and early childhood dietary practices. Unlike some food allergies, which outgrow with age, peanut allergies often persist into adulthood, thereby creating long-term demand for therapeutic management. This long-term chronic disease management drives the market, particularly for allergy management solutions, such as FDA-approved oral immunotherapy, desensitization therapies, and continuous emergency preparedness.

Additionally, this growing patient pool has led to closer clinical attention, increasing focus on earlier diagnosis by allergists and pediatricians, along with following structured treatment pathways. Schools and public institutions have implemented strict nut-free policies and specialized anaphylaxis action plans. Furthermore, as schools, healthcare providers, and public health systems are placing greater emphasis on allergy preparedness, this is indirectly supporting the demand for both preventive and emergency situations. The chronic nature of the condition also requires regular monitoring for desensitization efficacy, which increases clinical visits, outpatient care, and pharmacy interactions, accelerating the market for long-term peanut allergy therapeutics. Lastly, the market is anticipated to grow significantly due to the development of non-invasive therapies currently in the pipeline, such as the Viaskin Peanut Patch (Epicutaneous Immunotherapy - EPIT).

To learn more about this report, download the PDF brochure

Shift toward disease-modifying immunotherapies

Healthcare is transitioning from reactive to proactive care models, reshaping the therapeutic landscape of food allergies. Earlier, for peanut allergy management, the only protection was strictly avoiding peanuts, along with constant vigilance to avoid any accidental exposure and carrying epinephrine for the emergency administration in the event of an allergic reaction. However, with the introduction of oral immunotherapy, the focus has shifted toward modifying the immune response itself.

These therapies aim to increase the threshold of tolerance by introducing small, regulated amounts of allergen, thereby allowing patients to safely handle trace exposures. This protective buffer significantly reduces the severity of reactions following accidental exposure and alleviates chronic anxiety and social constraints, thereby improving the overall quality of life for patients and their families. Clinical adoption is supported by standardized dosing protocols, improved safety monitoring, and growing physician familiarity. In addition, pharmaceutical investment in allergy immunotherapy has intensified, leading to broader clinical trials and innovation in delivery mechanisms such as patches and injectables. This shift is gradually redefining treatment expectations and expanding the addressable market.

Drug Type Segment Outlook

The peanut allergy treatment market by drug type is categorized into antihistamines, epinephrine, immunotherapies, and others. Some of these drugs are used for symptomatic relief, while some are disease-modifying therapies. The epinephrine segment holds the largest share of the market, as it is widely adopted as a first-line emergency treatment due to its rapid action in reversing life-threatening conditions, particularly anaphylaxis. Antihistamine drugs, although generally used for managing mild allergic symptoms, including itching, hives, or nasal discomfort, still hold a significant share of the market for adjunctive management.

However, immunotherapies are the fastest- growing segment of the market. This segment is gaining traction by focusing on desensitizing patients to peanut allergens and addressing the underlying condition rather than just treating symptoms. Furthermore, immunotherapies are seeing increased growth as standardized protocols and approved treatments become more widely available, shifting focus from acute care to long-term proactive management.

To learn more about this report, download the PDF brochure

Regional Outlook: North America maintains its peanut allergy treatment market leadership

North America accounts for a substantial share of the market, which is mainly driven by the high prevalence of peanut allergies, advanced healthcare systems, and early adoption of immunotherapy products in the region. Moreover, the region also benefits from ongoing trials, strong R&D investments and favourable regulatory support for novel treatments, further strengthening the region's leading position in the global market. Europe follows North America with steady growth, driven by increasing awareness among patients and structured allergy management protocols. However, the adoption of new treatment varies across countries depending on their healthcare infrastructure and reimbursement policies.

Asia-Pacific is expected to witness faster expansion over the forecast period. Rapid urbanization, changing lifestyle and dietary patterns are contributing to rising incidences of food allergies in the region. Although the demand is high in the region, treatment adoption is hindered due to cost sensitivity and limited access to specialized healthcare services in rural areas.

Competitive Landscape Analysis

The global peanut allergy treatment market is marked by the presence of established and emerging market players such as DBV Technologies (France); Sanofi S.A. (France); ALK-Abelló A/S (Denmark); Prota Therapeutics (Australia); Camallergy (UK); Aravax Pty Ltd (Australia); Genentech (Roche Group) (US); Viatris Inc. (US), Intrommune Therapeutics (US); IgGenix, Inc. (US); and Regeneron Pharmaceuticals Inc. (US), among others.

Get a sample report for competitive landscape analysis

Growth strategies adopted by players to establish their foothold in the peanut allergy treatment market

Players operating in this market are adopting various growth strategies such as new product launches and approvals; acquisitions; expansions; and strategic partnerships, agreements, and collaborations, to garner market share. For instance,

• In March 2026, GSK completed the acquisition of RAPT Therapeutics to strengthen its immunology pipeline, including ozureprubart, a long-acting anti-IgE monoclonal antibody in Phase IIb development for protection against food allergens such as peanut, supporting the expansion of long-acting therapies targeting IgE-mediated allergic reactions
• In February 2024, Switzerland-based Roche announced FDA approval for Xolair (omalizumab), an anti-IgE therapy to reduce allergic reactions following accidental exposure to one or more foods, marking its expansion into food allergy management
• In January 2024, US-based Inimmune Corporation and Intrommune Therapeutics announced a collaboration to advance a rapid, long-acting oral mucosal immunotherapy for the treatment of peanut allergy, combining Intrommune’s disease-modifying peanut oral mucosal immunotherapy (OMIT) with Inimmune’s proprietary immunotherapy to enable rapid and long-term desensitization to peanut allergens

Report Scope

Global Peanut Allergy Treatment Market Segmentation

This report by Medi-Tech Insights provides the size of the global peanut allergy treatment market at the regional and country-level from 2024 to 2031. The report further segments the market by drug type, route of administration, age group, and distribution channel.

Market Size & Forecast (2024-2031), By Drug Type, USD Billion

• Antihistamines
• Epinephrine
• Immunotherapies
• Others

Market Size & Forecast (2024-2031), By Route of Administration, USD Billion

• Oral
• Injectable
• Others

Market Size & Forecast (2024-2031), By Age Group, USD Billion

• Paediatric
• Adult

Market Size & Forecast (2024-2031), By Distribution Channel, USD Billion

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Market Size & Forecast (2024-2031), By Region, USD Billion

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa